FTC Generic Drug Survey To Gather Information On Late-Listed Patents
This article was originally published in The Tan Sheet
Executive Summary
A Federal Trade Commission inquiry into generic drug competition will include an examination of late-listed patents.
You may also be interested in...
Generic Delay Tactics Evolving In Wake Of Consent Decrees – Initial FTC Data
Potentially anticompetitive strategies on generics have evolved since the Federal Trade Commission began imposing consent agreements on companies that made questionable settlements, FTC states
FTC
Drug patents should not be listed in Orange Book by FDA if they claim unapproved aspects of a drug, commission suggests in May 16 citizen petition to agency. "Any patent claiming only an unapproved component, an unapproved formulation or an unapproved use of a drug product" should not be allowed in Orange Book, FTC says. Petition comes in response to complaints from generic drug manufacturers that innovator companies are filing large numbers of late-listed patents to thwart private label competition. FTC is conducting an inquiry into this and other anticompetitive practices in drug industry (1"The Tan Sheet" Oct. 16, 2000, p. 13)
Hatch/Waxman Reform May See Quicker Action In Judiciary Under Leahy
Limited Hatch/Waxman reform proposals may be more likely to move through the Senate Judiciary Committee under incoming Chairman Patrick Leahy (D-Vt.).